Formations pour professionnels InhalopédiaPodcastsActualitésMentions légales
Coeur Poumons Coeur Poumons
 /  Maladies  / Maladies métaboliques  / Reflux gastro-œsophagien  /  Références

Reflux gastro-œsophagien

Partager cette page
Reflux gastro-œsophagien

Références

Partager cette page
En savoir plus

Références utilisées pour le contenu de cette section

  1. Ajmera A.V., Shastri G.S., Gajera M.J., Judge T.A. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;.19(3):.185
  2. Alvin JIng, Meng C. Ngu, Antony B.X. Bresli. The American Journal of Medicine. (2000) Obstructive sleep apnea and gastroesophageal reflux. https://doi.org/10.1016/S0002-9343(99)00350-2
  3. American Society for Gastrointestinal Endoscopy, https://www.asge.org/home/for-patients/patient-information/understanding-gerd-barrett-39-s (consulté 7 mars 2019).
  4. Ariel, H., & Cooke, J. P. (2019). Cardiovascular Risk of Proton Pump Inhibitors. Methodist DeBakey cardiovascular journal, 15(3), 214–219. https://doi.org/10.14797/mdcj-15-3-214
  5. Association Canadienne de gastroentérologie.
  6. Association Française de Formation Médicale Continue en Hépato-Gastro-Entérologie https://www.fmcgastro.org/postu-main/postu-2013-paris/textes-postu-2013-paris/traitement-du-rgo-indications-de-la-chirurgie/
  7. Canadian Cancer Statistics 2017.
  8. Canadian Digestive Health Foundation : https://cdhf.ca/fr/digestive-disorders/le-reflux-gastro-oesophagien-pathologique-rgo/foire-aux-questions-sur-le-rgo/ (page consultée le 31 janvier 2022)
  9. Dallaire C. (2002). Le reflux gastro-œsophagien. Le Médecin du Québec. Volume 37, numéro 2 (consulté le 3 juin 2021)
  10. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump
  11. Geevasinga N., Coleman P.L., Webster A.C., Roger S.D. Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol Hepatol. 2006 May; 4(5): 597-604.
  12. Groupe d’étude canadien sur les soins de santé préventifs (2019). https://canadiantaskforce.ca/adenocarcinome-oesophagien-resume-a-lintention-des-cliniciens/?lang=fr (consulté le 1 juin 2021).
  13. Groupe d’étude canadien sur les soins de santé préventifs (2019). https://canadiantaskforce.ca/lignesdirectrives/lignes-directrices-publiees/adenocarcinome-oesophagien/?lang=fr
  14. H. B. El-Serag, S. Sweet, C. C. Winchester et J. Dent, « Update on the epidemiology of gastro-œsophageal reflux disease: a systematic review », Gut, vol. 63, nᵒ 6 (2014), p. 871-880.
  15. Hess M.W., Hoenderop J.G., Bindels R.J., Drenth J.P. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012 Sep; 36(5): 405-13. Epub 2012 Jul 4.
  16. « How to Treat Heartburn », Tiré de http://howtotreatheartburn.com/how-to-wean-off-ppis-and-why/. Consulté le 15 décembre 2016.
  17. Hutchinson C., Geissler C.A., Powell J.J., Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;.56(9):.1291. Epub 2007 Mar 7.
  18. Hunt et collab. World Gastroenterology Organisation Global Guidelines, Journal of Clinical Gastroenterology: July 2017 – Volume 51 – Issue 6 – p 467-478 doi: 10.1097/MCG.0000000000000854 (consulté le 25 mai 2021)
  19. INESSS (2016). Usage optimal à long terme des inhibiteurs de la pompe à protons. Breton, M-C, Tremblay E. (consulté le 2 juin 2021).
  20. Initial treatment of gastroesophageal reflux disease. UpToDate. (2021)
  21. J. Richter, J. Pandolfino, M. Vela et collab., « Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group », Diseases of the Esophagus, vol. 26, nᵒ 8 (2013), p. 755‑765.
  22. Katz, Philip O MD; Gerson, Lauren B MD, MSc; Vela, Marcelo F MD, MSCR. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease, American Journal of Gastroenterology: March 2013 – Volume 108 – Issue 3 – p 308-328 doi: 10.1038/ajg.2012.444
  23. Lam J.R., Schneider J.L., Quesenberry C.P., Corley D.A. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology. 2017; 152(4): 821. Epub 2016 Nov. 24.
  24. Lam J.R., Schneider J.L., Zhao W., Corley D.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;.310(22):.2435.
  25. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification [archive], Gut, 1999;45:172-180, consulté le 20 mai 2021.
  26. Marcuard S.P., Albernaz L., Khazanie P.G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;.120(3):.211
  27. Matteo Ghisa, Brigida Barberio, Vincenzo Savarino et Elisa Marabotto, « The Lyon Consensus: Does It Differ From the Previous Ones? », Journal of Neurogastroenterology and Motility, vol. 26, no 3,‎ 30 juin 2020, p. 311–321 (ISSN 2093-0879 et 2093-0887, PMID 32606254, PMCID PMC7329153, DOI 10.5056/jnm20046, lire en ligne [archive], consulté le 4 novembre 2020.
  28. McColl K.E. Effect of proton pump inhibitors on vitamins and iron. Am. J. Gastroenterol. 2009;.104 Suppl. 2:.S5.
  29. Mizunashi K., Furukawa Y., Katano K., Abe K. Effect of omeprazole, an inhibitor of H+-K(+)-ATPase, on bone resorption in humans. Calcif. Tissue Int. 1993;.53(1):.21.
  30. Muriithi A.K., Leung N., Valeri A.M., Cornell L.D., Sethi S., Fidler M.E., Nasr S.H. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2014; 64(4): 558
  31. Ra A., Tobe S.W. Acute interstitial nephritis due to pantoprazole. Ann Pharmacother. 2004 Jan; 38(1): 41-5.
  32. Recker R.R. Calcium absorption and achlorhydria. N. Engl. J. Med. 1985;.313(2):.70.
  33. Reflux gastro-œsophagien, (2020). Lee Lynch K., Le Manuel Merck. Consulté le 15 mai 2021
  34. Sampathkumar K., Ramalingam R., Prabakar A., Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol. 2013; 23(4): 304.
  35. Sarzynski E., Puttarajappa C., Xie Y., Grover M., Laird-Fick H., Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig. Dis. Sci. 2011;.56(8):.2349.
  36. Scarpellini, E., Ang, D., Pauwels, A. et collab. Management of refractory typical GERD symptoms. Nat. Rev. Gastroenterol. Hepatol. 13, 281–294 (2016). https://doi.org/10.1038/nrgastro.2016.50
  37. Sifrim, D. & Zerbib, F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 61, 1340–1354 (2012).
  38. Sigterman, K. E., van Pinxteren, B., Bonis, P. A., Lau, J. & Numans, M. E. Short-term treatment with proton pump inhibitors, H2‑receptor antagonists and prokinetics for gastro-oesophageal reflux disease‑like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. 5, CD002095 (2013).
  39. Société nationale française de gastro-entérologie. (2018) Zerbib F., Conseils pratiques. Prise en charge du reflux gastro-œsophagien
  40. Tuukkanen J., Väänänen H.K. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif. Tissue Int. 1986;.38(2):.123.
  41. UpToDate (2021). Medical management of gastroesophageal reflux disease in adults.
  42. Zerbib, F., Sifrim, D., Tutuian, R., Attwood, S. & Lundell, L. Modern medical and surgical management of difficult-to-treat GORD.

Abonnez-vous à l'infolettre